- Home
- BCTX vs APM Comparison
BCTX vs APM Comparison
Compare BCTX & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- APM
- Stock Information
- Founded
- BCTX 2014
- APM 2010
- Country
- BCTX Canada
- APM United Kingdom
- Employees
- BCTX N/A
- APM N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- BCTX Health Care
- APM Health Care
- Exchange
- BCTX Nasdaq
- APM Nasdaq
- Market Cap
- BCTX 18.5M
- APM 18.9M
- IPO Year
- BCTX N/A
- APM 2018
- Fundamental
- Price
- BCTX $8.20
- APM $1.29
- Analyst Decision
- BCTX Strong Buy
- APM
- Analyst Count
- BCTX 1
- APM 0
- Target Price
- BCTX $40.00
- APM N/A
- AVG Volume (30 Days)
- BCTX 45.4K
- APM 106.4K
- Earning Date
- BCTX 12-15-2025
- APM 12-19-2025
- Dividend Yield
- BCTX N/A
- APM N/A
- EPS Growth
- BCTX N/A
- APM N/A
- EPS
- BCTX N/A
- APM N/A
- Revenue
- BCTX N/A
- APM N/A
- Revenue This Year
- BCTX N/A
- APM N/A
- Revenue Next Year
- BCTX N/A
- APM N/A
- P/E Ratio
- BCTX N/A
- APM N/A
- Revenue Growth
- BCTX N/A
- APM N/A
- 52 Week Low
- BCTX $6.00
- APM $0.59
- 52 Week High
- BCTX $190.50
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- BCTX 36.92
- APM 39.93
- Support Level
- BCTX $6.93
- APM $1.33
- Resistance Level
- BCTX $11.54
- APM $1.72
- Average True Range (ATR)
- BCTX 0.78
- APM 0.11
- MACD
- BCTX -0.39
- APM 0.02
- Stochastic Oscillator
- BCTX 22.77
- APM 19.61
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.